Vivus fell 4.2% to 13.72

Investor's Business Daily

Vivus (VVUS) fell 4.2% to 13.72 in heavy volume after Brean Capital downgraded the stock to sell from hold on lowered estimates for sales of its obesity drug Qsymia. Arena Pharmaceuticals (ARNA), which makes rival obesity drug Belviq, closed unchanged.

Rates

View Comments